Maria Beltran
Home Health · East Elmhurst, NYNPI 1558523761
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 269 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 34.8% of the total. Among home health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 269 payments — averaging $22.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$558
- AstraZeneca$443
- GSK$433
- Novo Nordisk$374
- Pfizer$284
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,156100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 84 | $2,147 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 38 | $558 |
| AstraZeneca | 21 | $443 |
| GSK | 19 | $433 |
| Novo Nordisk | 14 | $374 |
| Pfizer | 14 | $284 |
| Lilly USA, LLC | 12 | $276 |
| Bayer | 3 | $204 |
| Amarin Pharma, Inc. | 9 | $192 |
| Ironwood Pharmaceuticals, Inc | 8 | $180 |
| Boehringer Ingelheim | 7 | $163 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $129 |
| Axsome Therapeutics, Inc. | 4 | $116 |
| Exact Sciences | 3 | $83 |
| Nevro Corp. | 2 | $64 |
| Ardelyx, Inc. | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 2 | $49 |
| Daiichi Sankyo Inc. | 2 | $48 |
| Esperion Therapeutics, Inc. | 2 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Vanda Pharmaceuticals Inc. | 1 | $40 |
| Amgen | 2 | $37 |
| Merck | 2 | $31 |
| Vistapharm, Inc. | 2 | $27 |
| VBI Vaccine (delaware) Inc. | 1 | $24 |
| Redhill Biopharma Inc. | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Braintree Laboratories, Inc. | 1 | $20 |
| Boston Scientific | 1 | $18 |
| Phadia US Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,163 in reported general payments places this provider in the 95th percentile of 25 home health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 264 | $154,072 |
| JardianceEmpagliflozin | 122 | $129,638 |
| FarxigaDapagliflozin Propanediol | 101 | $100,013 |
| KerendiaFinerenone | 68 | $81,179 |
| LinzessLinaclotide | 64 | $58,847 |
| OzempicSemaglutide | 47 | $57,243 |
| TrulicityDulaglutide | 51 | $47,821 |
| JanuviaSitagliptin Phosphate | 31 | $30,750 |
| MounjaroTirzepatide | 21 | $28,235 |
| JanumetSitagliptin Phos/Metformin Hcl | 27 | $28,028 |
| XareltoRivaroxaban | 28 | $24,891 |
| RybelsusSemaglutide | 11 | $22,438 |
| TradjentaLinagliptin | 25 | $21,483 |
| EliquisApixaban | 19 | $18,011 |
| TrulancePlecanatide | 12 | $12,674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $163 | $151,122147 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $443 | $108,615116 claims |
| BayerKerendia | $204 | $81,17968 claims |
| Novo NordiskOzempic, Rybelsus | $374 | $79,68158 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $276 | $76,05672 claims |
| AbbVieLinzess, Namzaric | $2,147 | $69,07978 claims |
| MerckJanuvia, Janumet, Janumet Xr | $31 | $66,31669 claims |
| PfizerEliquis | $284 | $18,01119 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $558 | $12,67412 claims |
| GSKTrelegy Ellipta | $433 | $12,66011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 25 home health providers in New York.
Other home health in East Elmhurst
- Alexandra DuranteStaten Island$236
- Miriam SalernoEast Setauket$192
- Camilita Rahat-GoberdhanWhite Plains$187
- Mariamma BellamyMonroe$174
- Elizabeth KressWilliamsville$138
- Frank HallBuffalo$125
- Eileen PetersonOssining$125
- Melody DelgadoBronx$122
- Inah CastroFlushing$121
- Samantha BlackBrooklyn$108
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.